NCT07538960

Brief Summary

Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
350

participants targeted

Target at P75+ for all trials

Timeline
12mo left

Started May 2026

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress2%
May 2026May 2027

First Submitted

Initial submission to the registry

April 11, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

April 20, 2026

Completed
11 days until next milestone

Study Start

First participant enrolled

May 1, 2026

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2027

Last Updated

April 20, 2026

Status Verified

April 1, 2026

Enrollment Period

1 year

First QC Date

April 11, 2026

Last Update Submit

April 13, 2026

Conditions

Lymph Node CancerCutaneousT-cell Lymphoma

Keywords

LinfomaCutaneous LymphomaT-Cell LymphomaTherapy

Outcome Measures

Primary Outcomes (2)

  • Characterize the epidemiology

    Characterize the epidemiology of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México.

    2019-2025

  • Characterize the therapeutic management

    Characterize the therapeutic management of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México

    2019-2025.

Secondary Outcomes (7)

  • Describe the sociodemographic/epidemiological characteristics

    2019-2025

  • Classify the clinical manifestations/clinical subtypes

    2019-2025

  • Identify the histopathological/ immunohistochemical findings

    2019-2025

  • Analyze the therapeutic management modalities.

    2019-2025

  • identify the clinical stage at the time of diagnosis

    2019-2025

  • +2 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

he study population will consist of adult patients (≥18 years) of both sexes with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, and documented in EDUS at the Dermatology Service of Hospital México between January 2019 and December 2025. Patients must have at least one recorded dermatological evaluation during the study period and must have received some form of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic therapies. Patients with insufficient or incomplete clinical records that prevent adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution will be excluded, as well as those with a presumptive diagnosis without histopathological confirmation, duplicate or inconsistent records, patients attended outside the study period, those outside the defined age range, and patients.

You may qualify if:

  • Patients with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, documented in EDUS of Hospital México in the Dermatology Service of Hospital México during the period between January 2019 and December 2025.
  • Patients aged 18 years or older, of both sexes.
  • Patients with at least one dermatological evaluation recorded during the study period.
  • Patients who, having a confirmed diagnosis, have received some modality of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic treatments.

You may not qualify if:

  • Clinical records that are insufficient or incomplete, preventing adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution.
  • Patients with a presumptive diagnosis of cutaneous T-cell lymphoma without histopathological confirmation.
  • Duplicate or inconsistent records that hinder the correct identification and classification of the patient.
  • Patients attended outside the established study period.
  • Patients outside the age range.
  • Patients who do not belong to the Dermatology Service of Hospital México.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital México

San José, Uruca, 10107, Costa Rica

Location

MeSH Terms

Conditions

Lymphoma, T-CellLymphoma, T-Cell, Cutaneous

Condition Hierarchy (Ancestors)

Lymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Central Study Contacts

Daniel Barquero-Orias, Dermatologist

CONTACT

+506 83411026debarque@ccss.sa.cr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dermatologist

Study Record Dates

First Submitted

April 11, 2026

First Posted

April 20, 2026

Study Start

May 1, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 1, 2027

Last Updated

April 20, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

According to protocol

Locations

CO(1)